Explore our company news, announcements and updates

September 24, 2025

New Study Confirms Rapid Action of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets for the Treatment of Equine Protozoal Myeloencephalitis (EPM)

September 12, 2025

Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

August 19, 2025

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

August 18, 2025

Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

July 24, 2025

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

July 18, 2025

Merck Animal Health Announces FDA Approval of EXZOLT™ (fluralaner oral solution) for Chickens, the First Systemic Treatment for Northern Fowl Mites

July 10, 2025

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

June 12, 2025

Merck Animal Health Receives Positive Opinion from CVMP for NOBIVAC®L6 and NOBIVAC® LoVo L6 Vaccines for Use in Dogs Against Leptospirosis

June 12, 2025

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

May 16, 2025

Merck Animal Health Receives Positive CVMP Opinion for INNOVAX®-ND-IBD-ILT for Use in Chickens

May 8, 2025

Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

May 2, 2025

FDA Approves Merck Animal Health’s MOMETAMAX SINGLE™ to Treat Otitis Externa in Dogs

Previous 123 Next